文献速递儿童呼吸儿童感染

急诊科毛细支气管炎出院时药物治疗的国际差异:儿科急诊研究网络回顾性分析

Pharmacotherapy in bronchiolitis at discharge from emergency departments within the Pediatric Emergency Research Networks: a retrospective analysis.
PubMed 文献 · Lancet Child Adolesc Health · 2019-06-07

该研究基于儿科急诊研究网络的多国回顾性队列,纳入1566例<12月龄既往健康、2013年因毛细支气管炎从急诊出院的婴儿,发现20%出院时被处方药物(沙丁胺醇或皮质类固醇),各国处方率差异大,且出院用药与21天内急诊复诊或住院无关。

要点

  • 1566例出院婴儿中20%被处方药物治疗,皮质类固醇处方率0%-6%,沙丁胺醇处方率5%-32%。
  • 相比英国和爱尔兰,西班牙和葡萄牙、美国、加拿大处方药物的比值比升高。

核心结论

  • 急诊出院的毛细支气管炎婴儿使用无效药物常见,国家间和急诊科间处方实践差异大,需加强知识转化和去处方以优化管理。

研究设计与样本

  • 多国回顾性队列研究(儿科急诊研究网络)的计划二次分析,纳入38个急诊科2013年1月1日至12月31日出院、年龄<12月龄既往健康毛细支气管炎婴儿1566例。

主要发现

  • 1566例出院婴儿中317例(20%)被处方药物治疗。
  • 皮质类固醇处方率从西班牙和葡萄牙的0%(0/68)到美国的6%(25/452);沙丁胺醇处方率从英国和爱尔兰的5%(22/432)到美国的32%(146/452)。

关键数值与推荐

  • 临床指南建议毛细支气管炎不使用药物治疗。
  • 出院药物治疗处方率范围:皮质类固醇0%-6%,沙丁胺醇5%-32%。

临床怎么用

  • 儿科医生应遵循指南,避免对急诊出院的毛细支气管炎婴儿常规处方沙丁胺醇或皮质类固醇。
  • 需关注国家间和急诊科间处方差异,推动知识转化和去处方策略以统一管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical guidelines advise against pharmacotherapy in bronchiolitis. However, little is known about global variation in prescribing practices for bronchiolitis at discharge from emergency departments. We aimed to evaluate global variation in prescribing practice (ie, inhaled salbutamol, or oral or inhaled corticosteroids) for infants with bronchiolitis at discharge from emergency departments. METHODS: We did a planned secondary analysis of a multinational, retrospective cohort study of the Pediatric Emergency Research Networks. Previously healthy infants (aged <12 months) who were discharged with bronchiolitis between Jan 1 and Dec 31, 2013 from 38 emergency departments in Australia and New Zealand, Canada, Spain and Portugal, the UK and Ireland, and the USA were included. The primary outcome was pharmacotherapy prescription at discharge from the emergency department. Secondary outcomes were revisits to the emergency department or hospitalisations for bronchiolitis within 21 days of discharge. FINDINGS: Of 1566 infants discharged from the emergency department, 317 (20%) were prescribed pharmacotherapy. Corticosteroid prescriptions were infrequent, ranging from 0% (0 of 68 infants) in Spain and Portugal to 6% (25 of 452) in the USA. Salbutamol prescriptions ranged from 5% (22 of 432) in the UK and Ireland to 32% (146 of 452) in the USA. Compared with the UK and Ireland, the odds of prescription of pharmacotherapy were increased in Spain and Portugal (odds ratio [OR] 9·22, 95% CI 1·70-49·96), the USA (8·20, 2·79-24·11), Canada (5·17, 1·61-16·67), and Australia and New Zealand (1·21, 0·36-4·10). After adjustment for clustering by site, pharmacotherapy at discharge was associated with older age (per 1 month increase; OR 1·23, 95% CI 1·16-1·30), oxygen saturation (per 1% decrease from 100%; 1·09, 1·01-1·18), chest retractions (1·88, 1·26-2·79), network (p=0·00050), and site (p<0·00090). 303 (19%) of 1566 infants returned to the emergency department and 129 (43%) of 303 were hospitalised. Discharge pharmacotherapy was not associated with revisits (p=0·55) or subsequent hospitalisations (p=0·50). INTERPRETATION: Use of ineffective medications in infants with bronchiolitis at discharge from emergency departments is common, with large differences in prescribing practices between countries and emergency departments. Enhanced knowledge translation and deprescribing efforts are needed to optimise and unify the management of bronchiolitis. FUNDING: None.

来源:Lancet Child Adolesc Health,查看原文。版权归原作者所有。

引用

  1. Jamal A, Finkelstein Y, Kuppermann N, et al. Pharmacotherapy in bronchiolitis at discharge from emergency departments within the Pediatric Emergency Research Networks: a retrospective analysis. Lancet Child Adolesc Health. 2019. PMID: 31182422. doi:10.1016/S2352-4642(19)30193-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。